Infinity To Use Medidata RBM in Phase III Oncology Study

Nov 30, 2015
By Applied Clinical Trials Editors

Infinity Pharmaceuticals has expanded its use of the Medidata Clinical Cloud®, by utilizing its risk-based monitoring (RBM) solution in an upcoming Phase III oncology study for patients with indolent non-Hodgkin lymphoma.

Infinity has been a Medidata customer since 2005, utilizing the company’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®) across its pre-clinical and Phase I-III development programs. To further advance its drug development strategy and outsourcing model, Infinity is leveraging the combination of technology and analytics within Medidata RBM—including centralized statistical analytics, targeted source document verification (TSDV), and study and site level key risk indicators (KRIs).

Read the full release.

 

 

native1_300x100
lorem ipsum